BNZ 1

Drug Profile

BNZ 1

Alternative Names: BNZ-1; BNZ132-1; BNZ132-1-40

Latest Information Update: 21 Jul 2017

Price : $50

At a glance

  • Originator Bioniz
  • Developer Bioniz; National Institutes of Health (USA)
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Immunomodulators; Interleukin 15 receptor antagonists; Interleukin 2 receptor antagonists; Interleukin 9 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alopecia areata; T-cell leukaemia
  • Preclinical Tropical spastic paraparesis

Most Recent Events

  • 19 Jul 2017 Top-line adverse events data from a phase I in T-cell leukaemia released by Bioniz
  • 05 Jul 2017 Phase-I clinical trials in Alopecia areata in USA (unspecified route) prior to July 2017 (Bioniz pipeline, July 2017)
  • 05 Jun 2017 Bioniz completes a phase I trial in T-cell leukaemia (In volunteers) in USA (NCT03046459)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top